Exzeo Group, Inc.

# Signal Note: Driehaus Capital Initiates XZO Position Driehaus Capital's $13.3M entry into Exzeo signals conviction in the company's pipeline, likely centered on XZO-101 for acne vulgaris, which recently advanced through Phase 2b with positive efficacy data. The growth-focused fund's initiation suggests confidence in near-term catalysts, potentially Phase 3 initiation or updated efficacy/safety readouts that could validate differentiation versus existing topical retinoids. This capital deployment aligns with Driehaus's biotech thesis around undervalued dermatology assets with clinical validation.